The Antiphospholipid Syndrome and Pregnancy: Invited Review

References

• Conley C L, Hartmann R C. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952; 31: 621–2
   Web of Science ®Google Scholar
• Frick P G. Acquired circulating anticoagulants in systemic “collagen disease.” Auto‐immune thromboplastin deficiency. Blood 1955; 19: 691–706
   Google Scholar
• Bowie E J W, Thompson J H, Jr, Pascuzzi C A, Owen C A, Jr. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963; 62: 416–30
   PubMed Web of Science ®Google Scholar
• Feinstein D I, Rapaport S I. Acquired inhibitors of blood coagulation. Prog Hemost Thromb 1972; 1: 75–95
   PubMedGoogle Scholar
• Lechner K. Acquired inhibitors in nonhemophilic patients. Haemostasis 1974; 3: 65–93
   PubMedGoogle Scholar
• Laurell A B, Nilsson I M. Hypergamma‐globulinaemia, circulating anticoagulant, and biologic false positive Wassermann reaction: a study of 2 cases. J Lab Clin Med 1957; 49: 694–707
   PubMed Web of Science ®Google Scholar
• Nilsson I M, Astedt B, Hedner U, Berezin D. Intrauterine death and circulating anticoagulant (“antithromboplastin”). Acta Med Scan 1975; 197: 153–9
   PubMedGoogle Scholar
• Soulier J P, Boffa M C. Avortements a repetition, thromboses et anticoagulant circu‐lant antithromboplastine. trois observations. Nouv Presse Med 1989; 9: 859–64
   Google Scholar
• Firkin B G, Howard M A, Radford N. Possible relationship between lupus inhibitor and recurrent abortion in young women. Lancet 1980; ii: 366
   Google Scholar
• Boey M L, Colaco C B, Gharavi A E, Elkon K B, Loizou S, Hughes G R V. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J 1983; 287: 1021–3
   PubMed Web of Science ®Google Scholar
• Loeliger A. Prothrombin as co‐factor of the circulating anticoagulant in systemic lupus erythematosus?. Thromb Diath Haemorrh 1959; 3: 237
   Google Scholar
• Rapaport S I, Ames S B, Duvall B J. A plasma coagulation defect in systemic lupus erythematosus arising from hypoprothrombinemia combined with anti‐prothrom‐binase activity. Blood 1960; 15: 212
   PubMed Web of Science ®Google Scholar
• Fleck R A, Rapaport S I, Rao L V. Anti‐prothrombin antibodies and the lupus anticoagulant. Blood 1988; 72: 512–9
   PubMed Web of Science ®Google Scholar
• Thiagarajan P, Shapiro S S, De Marco L. Monoclonal immunoglobulin M coagulation inhibitor with phospholipid specificity, mechanism of lupus anticoagulant. J Clin Invest 1980; 66: 397–405
   PubMed Web of Science ®Google Scholar
• Shapiro S S, Thiagarajan P. Lupus anticoagulants. Prog Hemost Thromb 1982; 6: 263–85
   PubMedGoogle Scholar
• Colaco C B, Male D K. Anti‐phospholipid antibodies in syphilis and a thrombotic subset of SLE: distinct profiles of epitope specificity. Clin Exp Immunol 1985; 59: 449–56
   PubMedGoogle Scholar
• Harris E N, Gharavi A E, Boey M L, Patel B M, Mackworth‐Young C G, Loizou S, Hughes G R V. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; ii: 1211–4
   Google Scholar
• Loizou S, McCrea J D, Rudge A C, Reynolds R, Boyle C C, Harris E N. Measurement of anti‐cardiolipin antibodies by an enzyme‐linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin Exp Immunol 1985; 62: 738–45
   PubMed Web of Science ®Google Scholar
• Hughes G R V, Harris E N, Gharavi A E. The anticardiolipin syndrome. J Rheumatol 1986; 13: 486–9
   PubMed Web of Science ®Google Scholar
• Asherson R A, Khamashta M A, Hughes G R V. Antiphospholipid antibodies, lupus‐like disease and the primary antiphospholipid syndrome. Clin Rheumatol 1989; 8: 115–7
   PubMedGoogle Scholar
• Alarcon‐Segovia D, Sanchez‐Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989; 16: 482–8
   PubMed Web of Science ®Google Scholar
• Asherson R A, Khamashta M A, Ordi‐Ros J, Derksen R HWM, Machin S J, Barqui‐nero J, Outt H H, Harris E N, Vilardell‐Torres M, Hughes G R V. The primary antiphospholipid syndrome: major clinical and serological features. Medicine 1989; 68: 366–74
   PubMed Web of Science ®Google Scholar
• Carreras L O, Vermylen J G. Lupus anticoagulant and thrombosis–a possible role of inhibition of prostacyclin formation. Thromb Haemost 1982; 48: 38–40
   PubMed Web of Science ®Google Scholar
• Lechner K, Pabinger‐Fasching I. Lupus anticoagulants and thrombosis, a study of 25 cases and review of the literature. Haemostasis 1985; 15: 254–62
   PubMedGoogle Scholar
• Love P E, Santoro S A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non‐SLE disorders. Ann Intern Med 1990; 112: 682–98
   PubMed Web of Science ®Google Scholar
• Triplett D A, Brandt J T, Maas R L. The laboratory heterogeneity of lupus anticoagulants. Arch Pathol Lab Med 1985; 109: 946–51
   PubMed Web of Science ®Google Scholar
• Harris E N, Gharavi A E, Patel S P, Hughes G R V. Evaluation of the anti‐cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987; 68: 215–22
   PubMed Web of Science ®Google Scholar
• Ginsburg K S, Liang M H, Newcomer L, Goldhaber S Z, Schur P H, Hennekens C H, Stampfer M J. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117: 997–1002
   PubMed Web of Science ®Google Scholar
• Rosove M H, Brewer P M C. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303–8
   PubMed Web of Science ®Google Scholar
• Triplett D A. Antiphospholipid antibodies and thrombosis, a consequence, coincidence, or cause?. Arch Pathol Lab Med 1993; 117: 78–88
   PubMedGoogle Scholar
• Van Steenbergen W, Beyls J, Vermylen J, Fevery J, Marchal G, Desmet V, De Groote J. “Lupus” anticoagulant and thrombosis of the hepatic veins (Budd‐Chiari syndrome). report of three patients and review of the literature. J Hepatol 1986; 3: 87–94
   PubMedGoogle Scholar
• Vermylen J, Blockmans D, Spitz B, Arnout J, Grillet B. Thrombosis as an immune phenomenon. Bailliere's Clin Immunol Allergy 1987; 1: 619–41
   Google Scholar
• Asherson R A, Mackworth‐Young C G, Boey M L, Hull R G, Saunders A, Gharavi A E, Hughes G R. Pulmonary hypertension in systemic lupus erythematosus. Br Med J 1983; 287: 1024–5
   PubMed Web of Science ®Google Scholar
• Hamsten A, Norberg R, Björkholm M, de Faire E U, Holm G. Antibodies to cardio‐lipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986; i: 113–6
   Google Scholar
• Morton K E, Gavaghan T P, Krilis S A, Daggard G E, Baron D W, Hickie J B. Coronary artery bypass graft failure–an autoimmune phenomenon?. Lancet 1986; ii: 1353–7
   Google Scholar
• Englert H J, Hawkes C H, Boey M L, Derue G J, Loizou S, Harris E N, Gharavi A E, Hull R G, Hughes G R. Degos disease: association with anticardiolipin antibodies and the lupus anticoagulant. Br Med J 1984; 289: 576
   PubMedGoogle Scholar
• St Clair W, Jones B, Rogers J S, Crouch M, Hrabovsky E. Deep venous thrombosis and a circulating anticoagulant in systemic lupus erythematosus. Am J Dis Child 1981; 135: 230–2
   PubMedGoogle Scholar
• Bernstein M L, Salusinsky‐Stembach M, Bellefleur M, Esseltine D W. Thrombotic and hemorrhagic complications in children with the lupus anticoagulant. Am J Dis Child 1984; 138: 1132–5
   PubMedGoogle Scholar
• Contractor S, Hiatt M, Kosmin M, Kim H C. Neonatal thrombosis with anticardiolipin antibody in baby and mother. Am J Perinatol 1992; 9: 409–10
   PubMedGoogle Scholar
• Devilat M, Toso M, Morales M. Childhood stroke associated with protein C or S deficiency and primary antiphospholipid syndrome. Pediatr Neurol 1993; 9: 67–70
   PubMedGoogle Scholar
• Silver R K, MacGregor S N, Pasternak J F, Neely S E. Fetal stroke associated with elevated maternal anticardiolipin antibodies. Obstet Gynecol 1992; 80: 497–9
   PubMed Web of Science ®Google Scholar
• Ravelli A, Di Fuccia G, Caporali R, Malvezzi F, Montecucco C, Martini A. Severe retinopathy in systemic lupus erythematosus associated with IgG anticardiolipin antibodies. Acta Paediat 1993; 82: 624–6
   PubMedGoogle Scholar
• Derue G J, Englert H J, Harris E N, et al. Fetal loss in systemic lupus: association with anticardiolipin antibodies. J Obstet Gynaecol 1985; 5: 207–9
   Google Scholar
• Lockshin M D, Druzin M L, Goei S, Qamar T, Magid M S, Jovanovic L, Ferenc M. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med 1985; 313: 152–6
   PubMed Web of Science ®Google Scholar
• Ginsberg J S, Brill‐Edwards R, Johnston M, Denburg J A, Andrew M, Burrows R F, Bensen W, Cividino A, Long A A. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross‐sectional study. Blood 1992; 80: 975–80
   PubMed Web of Science ®Google Scholar
• McNeil H P, Chesterman C N, Krilis S A. Immunology and clinical importance of antiphospholipid antibodies. Advan Immunol 1991; 49: 193–280
   PubMed Web of Science ®Google Scholar
• Out H J, Bruinse H W, Christiaens G CML, Van Vliet M, de Groot P G, Nieuwenhuis H K, Derksen R HWM. A prospective, controlled multicenter study on the obstetric risk of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol 1992; 167: 26–32
   PubMed Web of Science ®Google Scholar
• Julkunen H, Jouhikainen T, Kaaja R, Leirisalo‐Repo M, Stephansson E, Palosuo T, Teramo K, Friman C. Fetal outcome in lupus pregnancy: a retrospective case‐control study of 242 pregnancies in 112 patients. Lupus 1993; 2: 125–131
   PubMed Web of Science ®Google Scholar
• MacLean M A, Cumming G P, McCall F, Walker I D, Walker J J. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. Br J Obstet Gynaecol 1994; 101: 103–6
   PubMedGoogle Scholar
• El‐Roeiy A, Myers S A, Gleicher N. The prevalence of autoantibodies and lupus anticoagulant in healthy pregnant women. Obstet Gynecol 1990; 75: 390–6
   PubMed Web of Science ®Google Scholar
• Rix P, Stentoft J, Aunsholt N A, Dueholm M, Tilma K A, Hoier‐Madsen M. Lupus anticoagulant and anticardiolipin antibodies in an obstetric population. Acta Obstet Gynecol Scand 1992; 71: 605–9
   PubMed Web of Science ®Google Scholar
• Lockwood C J, Romero R, Feinberg R F, Clyne L P, Coster B, Hobbins J C. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol 1989; 161: 369–73
   PubMed Web of Science ®Google Scholar
• Pattison N S, Chamley L W, McKay E J, Liggins G C, Butler W S. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynaecol 1993; 100: 909–13
   PubMedGoogle Scholar
• Hougie L, Bird A R. Lupus anticoagulant in pregnancy. Br J Haematol 1985; 60: 390–1
   Google Scholar
• Infante‐Rivard C, David M, Gauthier R, Rivard G E. Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. N Engl J Med 1991; 325: 1063–6
   PubMed Web of Science ®Google Scholar
• Harris E N, Spinnato J A. Should anticardiolipin tests be performed in otherwise healthy pregnant women?. Am J Obstet Gynecol 1991; 165: 1272–7
   PubMed Web of Science ®Google Scholar
• Aoki K, Hayashi Y, Hirao Y, Yagami Y. Specific antiphospholipid antibodies as a predictive variable in patients with recurrent pregnancy loss. Am J Reprod Immunol 1993; 29: 82–7
   PubMed Web of Science ®Google Scholar
• Branch D W, Andres R, Digre K B, Rote N S, Scott J R. The association of antiphospholipid antibodies with severe preeclampsia. Obstet Gynecol 1989; 73: 541–5
   PubMed Web of Science ®Google Scholar
• Harris E N, Chan J K H, Asherson R A, Aber V R, Gharavi A E, Hughes G R. Thrombosis, recurrent fetal loss and thrombocytopenia: predictive value of anticardiolipin antibody test. Arch Intern Med 1986; 146: 2153–9
   PubMedGoogle Scholar
• Loizou S, Byron M A, Englert H R, David J, Hughes G R, Walport M J. Association of quantitative anti‐cardiolipin antibody level with fetal loss and time of loss in systemic lupus erythematosus. Q J Med 1988; 68: 525–31
   PubMedGoogle Scholar
• Deleze M, Alarcon‐Segovia D, Valdes‐Macho E, Oria C V, Ponce de Leon S. Relationship between antiphospholipid antibodies and recurrent fetal loss in patients with systemic lupus erythematosus and apparently healthy women. J Rheumatol 1989; 16: 768–72
   PubMedGoogle Scholar
• Cowchock S, Fort J, Munoz S, Norberg R, Maddrey W. False positive ELISA tests for anticardiolipin antibodies in sera from patients with repeated abortion, rheuma‐tologic disorders and primary biliary cirrhosis: correlation with elevated polyclonal IgM and implications for patients with repeated abortion. Clin Exp Immunol 1988; 73: 289–94
   PubMedGoogle Scholar
• Harris E N. The Second International Anti‐Cardiolipin Standardization Workshop/ The Kingston Anti‐Phospholipid Antibody Study (KAPS) Group. Am J Clin Pathol 1990; 94: 476–84
   PubMed Web of Science ®Google Scholar
• Qamar T, Levy R A, Sammaritano L, Gharavi A E, Lockshin M D. Characteristics of high‐titer IgG antiphospholipid antibody in systemic lupus erythematosus patients with and without fetal death. Arthritis Rheum 1990; 33: 501–4
   PubMedGoogle Scholar
• Harris E N. Maternal autoantibodies and pregnancy–I: the antiphospholipid antibody syndrome. Bailliere's Clin Rheumatol 1990; 4: 53–68
   PubMedGoogle Scholar
• Lubbe W F, Butler W S, Palmer S J, Liggins G C. Fetal survival after prednisone suppression of maternal lupus anticoagulant. Lancet 1983; i: 1361–3
   Google Scholar
• Lubbe W F, Butler W S, Palmer S J, Liggins C G. Lupus anticoagulant in pregnancy. Br J Obstet Gynaecol 1984; 91: 357–63
   PubMedGoogle Scholar
• De Wolf F, Carreras L O, Moerman P, Vermylen J, Van Assche A, Renaer M. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss and a lupus anticoagulant. Am J Obstet Gynecol 1982; 142: 829–34
   PubMed Web of Science ®Google Scholar
• Out H J, Kooijman C D, Bruinse H W, Derksen R HWM. Histopathological findings in placentae from patients with intra‐uterine fetal death and anti‐phospholipid antibodies. Eur J Obstet Gynecol Reprod Biol 1991; 41: 179–86
   PubMed Web of Science ®Google Scholar
• Labarerre C A, Catoggio L J, Mullen E G, Althabe O H. Placental lesions in maternal autoimmune disease. Am J Reprod Immunol Microbiol 1986; 12: 78–86
   PubMedGoogle Scholar
• Mari G, Wasserstrum N. Flow velocity waveforms of the fetal circulation preceding fetal death in a case of lupus anticoagulant. Am J Obstet Gynecol 1991; 164: 776–8
   PubMedGoogle Scholar
• Carroll B A. Obstetric duplex sonography in patients with lupus anticoagulant syndrome. J Ultrasound Med 1990; 9: 17–21
   PubMedGoogle Scholar
• Trudinger B J, Stewart G J, Cook C M, Connelly A, Exner T. Monitoring lupus anticoagulant‐positive pregnancies with umbilical artery flow velocity waveforms. Obstet Gynecol 1988; 72: 215–8
   PubMedGoogle Scholar
• Kwak J Y H, Gilman‐Sachs A, Beaman K D, Beer A E. Reproductive outcome in women with recurrent spontaneous abortions of alloimmune and autoimmune causes: Preconception versus postconception treatment. Am J Obstet Gynecol 1992; 166: 1787–98
   PubMedGoogle Scholar
• Bendon R W, Wilson J, Getahun B, van der Bel‐Kahn J. A maternal death due to thrombotic disease associated with anticardiolipin antibody. Arch Path Lab Med 1987; 11: 370–3
   Google Scholar
• Ishizuka T, Suzuki K, Hara M, et al. A case of a pregnant woman with lupus anticoagulant positive systemic lupus erythematosus complicated by intra‐uterine death, eclampsia and brainstem vascular damage. Jpn J Rheumatol 1992; 4: 11–20
   Google Scholar
• Wilson J J, Zahn C A, Ross S D, Newman H. Association of embolic stroke in pregnancy with the lupus anticoagulant, a case report. J Reprod Med 1986; 31: 725–8
   PubMedGoogle Scholar
• Greenspoon J S. Cerebral infarction, lupus anticoagulant and habitual abortion. J Am Med Assoc 1986; 255: 2164
   Google Scholar
• Farquharson R G, Compston A, Bloom A L. Lupus anticoagulant: a place for prepregnancy treatment?. Lancet 1985; ii: 842–3
   Google Scholar
• Kalashnikova L A, Prudnikova L Z, Nasonov E P. Cerebrovascular disorders associated with livedo (Sneddon's syndrome): its relationship to lupus anticoagulant. Zh Nevropatol Psikhiatr IMSS Korsakova 1990; 90: 104–7
   PubMedGoogle Scholar
• Mor F, Beigel Y, Inbal A, Goren M, Wysenbeek A J. Hepatic infarction in a patient with the lupus anticoagulant. Arthritis Rheum 1989; 32: 491–5
   PubMedGoogle Scholar
• Lubbe W F, Walkom P, Alexander C J. Hepatic and splenic haemorrhage as a complication of toxaemia of pregnancy in a patient with circulating lupus anticoagulant. NZ Med J 1982; 95: 842–4
   PubMedGoogle Scholar
• Grottolo A, Ferrari V, Mariano M, Zambruni A, Tincani A, Del Bono R. Primary adrenal insufficiency, circulating lupus anticoagulant and anticardiolipin antibodies in a patient with multiple abortions and recurrent thrombotic episodes. Haemato‐logica 1988; 73: 517–9
   PubMedGoogle Scholar
• Kincaid‐Smith P. Post partum renal failure in systemic lupus erythematosus associated with circulating lupus anticoagulant and anticardiolipin antibody. Clin Nephrol 1991; 36: 52
   PubMedGoogle Scholar
• Rao A A, Ananthakrishna N C. Anticardiolipin antibodies in eclampsia. Int J Gynecol Obstet 1992; 38: 37–40
   PubMedGoogle Scholar
• Rajah S B, Moodley J, Pudifin D, Duursma J. Anticardiolipin antibodies in hypertensive emergencies in pregnancy. Clin Exp Hypertens Part B Hypertens Pregnancy 1990; 9: 267–71
   Web of Science ®Google Scholar
• Rafla N, Farquharson R. Lupus anticoagulant in preeclampsia and intra‐uterine growth retardation. Eur J Obstet Gynecol Reprod Biol 1991; 42: 167–70
   PubMed Web of Science ®Google Scholar
• Kochenour N K, Branch D W, Rote N S, Scott J R. A new postpartum syndrome associated with antiphospholipid antibodies. Obstet Gynecol 1987; 69: 460–8
   PubMed Web of Science ®Google Scholar
• Sheridan‐Pereira M, Porreco R P, Hays T, Burke M S. Neonatal aortic thrombosis associated with the lupus anticoagulant. Obstet Gynecol 1988; 71: 1016–8
   PubMedGoogle Scholar
• Finazzi G, Cortelazzo S, Viero P, Galli M, Barbui T. Maternal lupus anticoagulant and fatal neonatal thrombosis. Thromb Haemostas 1987; 58: 238
   Google Scholar
• Levine R S, Welch K M A. The spectrum of neurologic disease associated with antiphospholipid antibodies. Arch Neurol 1987; 44: 876–83
   PubMedGoogle Scholar
• The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993; 43: 2069–73
   PubMedGoogle Scholar
• Stephens C J M. The antiphospholipid syndrome, clinical correlations, cutaneous features, mechanism of thrombosis and treatment of patients with the lupus anticoagulant and anticardiolipin antibodies. Br J Dermatol 1991; 125: 199–210
   PubMedGoogle Scholar
• Carreras L O, Defreyn G, Machin S J, Vermylen J, Deman R, Spitz B, Van Assche A. Arterial thrombosis, intrauterine death and “lupus” anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981; i: 244–6
   Google Scholar
• McVerry B A, Machin S J, Parry H, Goldstone A H. Reduced prostacyclin activity in systemic lupus erythematosus. Ann Rheum Dis 1980; 39: 524–5
   PubMed Web of Science ®Google Scholar
• Elias M, Eldor A. Thromboembolism in patients with the ‘lupus’‐type circulating anticoagulant. Arch Intern Med 1984; 144: 510–5
   PubMedGoogle Scholar
• Vila L, de Castellarnau C, Borrell M. Lupus anticoagulant and vascular prostacyclin production. Thromb Haemostas 1985; 45: 38
   Google Scholar
• Gregorini G, Setti G, Remuzzi G. Recurrent abortion with lupus anticoagulant, and preeclampsia: a common final pathway for two different diseases? Case report. Br J Obstet Gynaecol 1986; 93: 194–6
   PubMedGoogle Scholar
• Carreras L O, Vermylen J G. “Lupus” anticoagulant and thrombosis; possible role of inhibition of prostacyclin formation. Thromb Haemostas 1982; 48: 38–40
   PubMed Web of Science ®Google Scholar
• Hasselaar P, Derksen R HWM, Blokzijl L, de Groot P G. Thrombosis associated with antiphospholipid antibodies cannot be explained by effects on endothelial and platelet prostanoid synthesis. Thromb Haemostas 1988; 59: 80–5
   PubMed Web of Science ®Google Scholar
• Dudley D J, Mitchell M D, Branch D W. Pathophysiology of antiphospholipid antibodies: absence of prostaglandin‐mediated effects on cultured endothelium. Am J Obstet Gynecol 1990; 162: 953–9
   PubMedGoogle Scholar
• Schinco P C, Marranca D, Bazzan M, Borchiellini A, Fantino A, Gavis G, Melzi E, Modena V, Tamponi G, Tavella A M, Fantino A, Goris G, Melzi E, Modena V, Tampani G, Tavella A M, Pileri A, Benedetto C. Lupus Anticoagulant: Interference with in vivo, prostaglandin production and with platelet sensitivity to prostacyclin. Scand J Rheumatol 1992; 21: 124–8
   PubMed Web of Science ®Google Scholar
• Walker T S, Triplett D A, Javed N, Musgrave K. Evaluation of lupus anticoagulants: antiphospholipid antibodies, endothelium associated immunoglobulin, endothelial prostacyclin secretion, and antigenic protein S levels. Thromb Res 1988; 51: 267–81
   PubMed Web of Science ®Google Scholar
• Lindsey N, Henderson F, Malia R, Greaves M, Hughes P. Serum masks the inhibition of thrombin‐induced prostacyclin release produced by anticardiolipin antibodies. Br J Rheumatol 1992; 31: 179–83
   PubMedGoogle Scholar
• Watson K V, Schorer A E. Lupus anticoagulant inhibition of in vitro, prostacyclin release is associated with a thrombosis‐prone subset of patients. Am J Med 1991; 90: 47–53
   PubMedGoogle Scholar
• Schorer A E, Duane P G, Woods V L, Niewoehner D E. Some antiphospholipid antibodies inhibit phospholipase A2 activity. J Lab Clin Med 1992; 120: 67–77
   PubMedGoogle Scholar
• Leilouche F, Martinuzzo M, Said P, Maclouf J, Carreras L O. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood 1991; 78: 2894–9
   PubMedGoogle Scholar
• Martinuzzo M E, Maclouf J, Carreras L O, Levy‐Toledano S. Antiphospholipid antibodies enhance thrombin‐induced platelet activation and thromboxane formation. Thromb Haemostas 1993; 70: 667–71
   PubMed Web of Science ®Google Scholar
• Kaaja R, Julkunen H, Viinikka L, Ylikorkala O. Production of prostacyclin and thromboxane in lupus pregnancies: effect of small dose of aspirin. Obstet Gynecol 1993; 81: 327–31
   PubMed Web of Science ®Google Scholar
• Peaceman A M, Rehnberg K A. The immunoglobulin G fraction from plasma containing antiphospholipid antibodies causes increased placental thromboxane production. Am J Obstet Gynecol 1992; 167: 1543–7
   PubMed Web of Science ®Google Scholar
• Comp P C, De Bault L E, Esmon N L, Esmon C T. Human thrombomodulin is inhibited by IgG from two patients with non specific anticoagulants. Blood 1983; 62(suppl I)299
   Google Scholar
• Freyssinet J M, Cazenave J P. Lupus‐like anticoagulants, modulation of the protein C pathway and thrombosis. Thromb Haemostas 1987; 58: 679–81
   PubMedGoogle Scholar
• Cariou R, Tobelem G, Bellucci S, Soria J, Soria C, Maclouf J, Caen J. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells–inhibition of thrombomodulin‐dependent protein C activation. Thromb Haemostas 1988; 60: 54–8
   PubMed Web of Science ®Google Scholar
• Marciniak E, Romond E H. Impaired catalytic function of activated protein C: a new in vitro, manifestation of lupus anticoagulant. Blood 1989; 74: 2426–32
   PubMedGoogle Scholar
• Moreb J, Kitchens C S. Acquired functional protein S deficiency, cerebral venous thrombosis, and coumarin skin necrosis in association with antiphospholipid syndrome: report of two cases. Am J Med 1989; 87: 207–10
   PubMed Web of Science ®Google Scholar
• Kordich L C, Forastiero R R, Basilotta E, Porterie P, Carreras L O. Natural inhibitors of blood coagulation and fibrinolysis in patients with lupus anticoagulant. Blood Coagulat Fibrinol 1992; 3: 765–71
   PubMedGoogle Scholar
• Cosgriff T M, Martin B A. Low‐functional and high‐antigenic antithrombin III level in a patient with the lupus anticoagulant and recurrent thrombosis. Arthritis Rheum 1981; 24: 94–6
   PubMed Web of Science ®Google Scholar
• Angles‐Cano E, Sultan Y, Clauvel J P. Predisposing factors to thrombosis in systemic lupus erythematosus. Possible relation to endothelial cell damage. J Lab Clin Med 1979; 94: 312–23
   PubMed Web of Science ®Google Scholar
• Sanfelippo M J, Drayna C J. Prekallikrein inhibition associated with the lupus anticoagulant: a mechanism of thrombosis. Am J Clin Pathol 1982; 77: 275–9
   PubMed Web of Science ®Google Scholar
• Tsakiris D A, Marbet G A, Makris P E, Settas L, Duckert F. Impaired fibrinolysis as an essential contribution to thrombosis in patients with lupus anticoagulant. Thromb Haemostas 1989; 61: 175–7
   PubMedGoogle Scholar
• Francis R B, Jr, Neelye S. Effect of the lupus anticoagulant on endothelial fibronlytic activity in vitro. Thromb Haemostas 1989; 61: 314–7
   PubMedGoogle Scholar
• Ferro D, Violi F, Quintarelli C, Sebastianelli A, D'Amelio R, Zichella L, Balsano F. Fibrinolytic balance and lupus anticoagulant in patients with repeated spontaneous fetal loss. Br Med J 1992; 305: 504–5
   PubMedGoogle Scholar
• Francis R B, Jr, McGehee W G, Feinstein D I. Endothelial‐dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis. Thromb Haemostas 1988; 59: 412–4
   PubMedGoogle Scholar
• Ferro D, Quintarelli C, Rasura M, Antonini G, Violi F. Lupus anticoagulant and the fibrinolytic system in young patients with stroke. Stroke 1993; 224: 368–70
   Google Scholar
• Thiagarajan P, Tait J F. Binding of annexin V/placental anticoagulant protein 1 to platelets; Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J Biol Chem 1990; 265: 17420–3
   PubMedGoogle Scholar
• Sammaritano L R, Gharavi A E, Soberano C, Levy R A, Michael D, Lockshin M D. Phospholipid binding of antiphospholipid antibodies and placental anticoagulant protein. J Clin Immunol 1992; 12: 27–35
   PubMedGoogle Scholar
• Hasselaar P, Derksen R H, Oosting J D, Blokzijl L, de Groot P G. Synergistic effect of low doses of tumor necrosis factor and sera from patients with systemic lupus erythematosus on the expression of procoagulant activity by cultured endothelial cells. Thromb Haemostas 1989; 62: 654–60
   PubMedGoogle Scholar
• Oosting J D, Derksen R H, Blokzijl L, Sixma J J, de Groot P G. Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity: studies in a thrombosis model. Thromb Haemostas 1992; 68: 278–84
   PubMed Web of Science ®Google Scholar
• Branch D W, Rodgers G M. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol 1993; 168: 206–10
   PubMedGoogle Scholar
• McNeil H P, Simpson R J, Chesterman C N, Krilis S A. Anti‐phospholipid antibodies are directed against a complex antigen that includes a lipid‐binding inhibitor of coagulation: a2‐glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120–4
   PubMed Web of Science ®Google Scholar
• Galli M, Comfurius P, Maassen C, Hemker H C, de Baets M H, van Breda‐Vriesman P J C, Barbui T, Zwaal R F A, Bevers E M. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544–7
   PubMed Web of Science ®Google Scholar
• Pierangeli S S, Harris E N, Davis S A, DeLorenzo G. Beta‐2‐gIycoprotein 1 (beta2GPl) enhances cardiolipin binding activity but is not the antigen for anti‐phospholipid antibodies. Br J Haematol 1992; 82: 565–70
   PubMed Web of Science ®Google Scholar
• Arvieux J, Roussel B, Jacob M C, Colomb M G. Measurement of anti‐phospholipid antibodies by EL1SA using beta‐2‐glycoprotein I as an antigen. Journal of immunological methods 1991; 143: 223–9
   PubMed Web of Science ®Google Scholar
• Wagenknecht D R, McLntyre J A. Changes in beta‐2‐glycoprotein I antigenicity induced by phospholipid binding. Thromb Haemostas 1993; 69: 361–5
   PubMedGoogle Scholar
• Schousboe I. Beta‐2‐glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 1086–91
   PubMed Web of Science ®Google Scholar
• Nimpf J, Bevers E M, Bomans P H H, Till U, Wurm H, Kostner G M, Zwaal R F A. Prothrombinase activity of human platelets is inhibited by beta‐2‐glycoprotein‐I. Biochim Biophys Acta 1986; 884: 142–9
   PubMed Web of Science ®Google Scholar
• Nimpf J, Wurm H, Kostner G M. Interaction of beta‐2‐glycoprotein‐I with human blood platelets: influence upon the ADP‐induced aggregation. Thromb Haemostas 1985; 54: 397–401
   PubMed Web of Science ®Google Scholar
• Schousboe I. Inositolphospholipid‐accelerated activation of prekallikrein by activated factor XII and its inhibition by beta‐2‐glycoprotein I. Eur J Biochem 1988; 176: 629–36
   PubMedGoogle Scholar
• Laszlo F JMM, van der Linden I K, Bertina R M. Beta‐2‐glycoprotein I deficiency and the risk of thrombosis. Thromb Haemostas 1992; 67: 649–53
   PubMedGoogle Scholar
• Bevers E M, Galli M, Barbui T, Comfurius P, Zwaal R F A. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid‐bound human prothrombin. Thromb Haemostas 1991; 66: 629–32
   PubMed Web of Science ®Google Scholar
• Roubey R A, Pratt C W, Buyon J P, Winfield J B. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta‐2‐glycoprotein I. J Clin Invest 1992; 90: 1100–4
   PubMedGoogle Scholar
• Oosting J D, Derksen R HWM, Entjes H T I, Bouma B N, de Groot P G. Lupus anticoagulant activity is frequently dependent on the presence of beta‐2‐glycoprotein I. Thromb Haemostas 1992; 67: 499–502
   PubMed Web of Science ®Google Scholar
• Vermylen J, Arnout J. Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid‐protein complexes?. J Lab Clin Med 1992; 120: 10–12
   PubMedGoogle Scholar
• Oosting J D, Derksen R HWM, Bobbink I W G, Hackeng T M, Bouma B N, de Groot P G. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?. Blood 1993; 81: 2618–25
   PubMed Web of Science ®Google Scholar
• Branch D W, Dudley D J, Mitchell M D, Creighton K A, Abbott T M, Hammond E H, Daynes R A. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990; 163: 210–6
   PubMed Web of Science ®Google Scholar
• Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti‐phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti‐cardiolipin antibodies. Proc Natl Acad Sci USA 1991; 88: 3069–73
   PubMed Web of Science ®Google Scholar
• Bakimer R, Fishman P, Blank M, Sredni B, Djaldetti M, Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H‐3). J Clin Invest 1992; 89: 1558–63
   PubMed Web of Science ®Google Scholar
• Krause I, Blank M, Gilbrut B, Shoenfeld Y. The effect of aspirin on recurrent fetal loss in experimental antiphospholipid syndrome. Am J Reprod Immunol 1993; 29: 155–61
   PubMed Web of Science ®Google Scholar
• Bakimer R, Guilburd B, Zurgil N, Shoenfeld Y. The effect of intravenous gammaglobulin on the induction of experimental antiphospholipid syndrome. Clin Immunol Immunopathol 1993; 69: 97–102
   PubMedGoogle Scholar
• Inbar O, Blank M, Faden D, Tincani A, Lorber M, Shoenfeld Y. Prevention of fetal loss in experimental antiphospholipid syndrome by low‐molecular‐weight heparin. Am J Obstet Gynecol 1993; 169: 423–6
   PubMed Web of Science ®Google Scholar
• Fishman P, Falach‐Vaknine E, Zigelman R, Bakimer R, Sredni B, Djaldetti M, Shoenfeld Y. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo, administration of recombinant interleukin‐3. J Clin Invest 1993; 91: 1834–7
   PubMed Web of Science ®Google Scholar
• Hamilton J A, Vairo K R, Knight K G, Cocks B G. Activation and proliferation signals in murine macrophages, biochemical signals controlling the regulation of macrophage urokinase type plasminogen activator activity by colony stimulating factors and other agents. Blood 1991; 77: 616–27
   PubMed Web of Science ®Google Scholar
• McCrae K R, DeMichele A M, Pandhi P, Balsai M J, Samuels P, Graham C, Lala P K, Cines D B. Detection of antitrophoblast antibodies in the sera of patients with anticardiolipin antibodies and fetal loss. Blood 1993; 82: 2730–41
   PubMedGoogle Scholar
• Exner T, Triplett D A, Taberner D, Machin S J. Guidelines for testing and revised criteria for lupus anticoagulants. Thromb Haemostas 1991; 65: 320–2
   PubMed Web of Science ®Google Scholar
• Margolius A, Jackson D P, Ratnoff O D. Circulating anticoagulants: a study of 40 cases and a review of the literature. Medicine 1961; 40: 145–202
   PubMed Web of Science ®Google Scholar
• Gastineau D A, Kazmier F J, Nichols W L, Bowie E J W. Lupus anti coagulant: an analysis of the clinical and laboratory features of 219 cases. Am J Hematol 1985; 19: 265–75
   PubMedGoogle Scholar
• Exner T, Rickard K A, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 1978; 40: 143–51
   PubMed Web of Science ®Google Scholar
• Rosner E, Pauzner R, Lusky A, Modan M, Many A. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemostas 1987; 57: 144–7
   PubMed Web of Science ®Google Scholar
• Thiagarajan P, Pengo V, Shapiro S S. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986; 68: 869–74
   PubMed Web of Science ®Google Scholar
• Schleider M A, Nachman R L, Jaffe E A, Coleman M. A clinical study of the lupus anticoagulant. Blood 1976; 48: 499–510
   PubMed Web of Science ®Google Scholar
• Mannucci P M, Canciani M T, Man D, Meucci P. The varied sensitivity of partial thromboplastin time reagents in the demonstration of the lupus‐like anticoagulant. Scand J Haematol 1979; 22: 423–32
   PubMedGoogle Scholar
• Alving B M, Baldwin P E, Richards R L, Jackson B J. The dilute phospholipid APTT: a sensitive assay for verification of lupus anticoagulants. Thromb Haemostas 1985; 54: 709–12
   PubMedGoogle Scholar
• Brandt J T, Triplett D A. The effect of phospholipid on the detection of lupus anticoagulants by the dilute russell viper venom time. Arch Pathol Lab Med 1989; 113: 1376–8
   PubMed Web of Science ®Google Scholar
• Forastiero R R, Falcon C R, Carreras L O. Comparison of various screening and confirmatory tests for the detection of the lupus anticoagulant. Haemostasis 1990; 20: 208–14
   PubMedGoogle Scholar
• Exner T. Comparison of two simple tests for the lupus anticoagulant. Am J Clin Pathol 1985; 83: 215–8
   PubMed Web of Science ®Google Scholar
• Lesperance B, David M, Rauch J, Infante‐Rivard C, Rivard G E. Relative sensitivity of different tests in the detection of low titer lupus anticoagulants. Thromb Haemostas 1988; 60: 217–9
   PubMedGoogle Scholar
• Lo S C L, Oldmeadow M J, Howard M A, Firkin B G. Comparison of laboratory tests used for identification of the lupus anticoagulant. Am J Hematol 1989; 30: 213–20
   PubMed Web of Science ®Google Scholar
• Brandt J T, Triplett D A, Musgrave K, Orr C. The sensitivity of different coagulation reagents to the presence of lupus anticoagulant. Arch Pathol Lab Med 1987; 111: 120–4
   PubMedGoogle Scholar
• Arnout J, Vanrusselt M, Huybrechts E, Vermylen J. Optimisation of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin. Br J Haematol 1994; 87: 94–9
   PubMed Web of Science ®Google Scholar
• Brien F, Schaus M R, Cooper K E, O'Keefe B T, Inwood M. Lupus anticoagulant testing: effect of the platelet count on the activated partial thromboplastin time. Br J Biomed Sci 1993; 50: 114–6
   PubMedGoogle Scholar
• Triplett D A, Brandt J T. Lupus anticoagulants: misnomer, paradox, riddle, epi‐phenomenon. Hematol Pathol 1988; 2: 121–143
   PubMedGoogle Scholar
• Rosove M H, Ismail M, Koziol B J, Runge A, Kasper C K. Lupus anticoagulants: improved diagnosis with a kaolin clotting time using rabbit brain phospholipid in standard and high concentrations. Blood 1986; 68: 472–8
   PubMed Web of Science ®Google Scholar
• Triplett D A, Brandt J T, Kaczor D, Schaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983; 79: 678–82
   PubMed Web of Science ®Google Scholar
• Dahlback B, Nilsson I M, Frohm B. Inhibition of platelet prothrombinase activity by a lupus anticoagulant. Blood 1983; 62: 218–25
   PubMed Web of Science ®Google Scholar
• Al‐Mondhiry H, Galanakis D. Dysfibrinogenemia and lupus anticoagulant in a patient with recurrent thrombosis. J Lab Clin Med 1987; 110: 726–33
   PubMedGoogle Scholar
• Fox J E B. The platelet cytoskeleton. Thrombosis and Haemostasis, M Verstraete, J Vermylen, H R Lijnen, J Arnout, 1987; 525–47
   Google Scholar
• Arnout J, Huybrechts E, Vanrusselt M, Vermylen J. A New lupus anticoagulant neutralization test based on platelet‐derived vesicles. Br J Haematol 1992; 80: 341–6
   PubMedGoogle Scholar
• Kelsey P R, Stevenson K J, Poller L. The diagnosis of lupus anticoagulants by the activated partial thromboplastin time: the central role of phosphatidylserine. Thromb Haemostas 1984; 52: 172–5
   PubMedGoogle Scholar
• Rauch J, Tannenbaum M, Janoff A S. Distinguishing plasma lupus anticoagulants from anti‐factor antibodies using hexagonal (II) phase phospholipids. Thromb Haemostas 1989; 62: 892–6
   PubMed Web of Science ®Google Scholar
• Khamashta M A, Hughes G R V. Detection and importance of anticardiolipin antibodies. J Clin Pathol 1993; 46: 104–7
   PubMed Web of Science ®Google Scholar
• Peaceman A M, Silver R K, MacGregor S N, Socol M L. Interlaboratory variation in antiphospholipid antibody testing. Am J Obstet Gynecol 1992; 166: 1780–7
   PubMed Web of Science ®Google Scholar
• Lubbe W F, Butler W S, Palmer S J, Liggins G C. Fetal survival after prednisone suppression of maternal lupus‐anticoagulant. Lancet 1983; i: 1361–4
   Google Scholar
• Spitz B, Van Assche F A, Vermylen J. Lupus anticoagulant and pregnancy. Am J Obstet Gynecol 1986; 154: 1169
   PubMedGoogle Scholar
• Out H J, Bruinse H W, Derksen R HWM. Anti‐phospholipid antibodies and pregnancy loss. Hum Reprod 1992; 6: 889–97
   Google Scholar
• Branch D W, Scott J R, Kochenour N K, Hershgold E. Obstetric complications associated with the lupus anticoagulant. N Engl J Med 1985; 313: 1322–6
   PubMed Web of Science ®Google Scholar
• Lockshin M D, Druzin M L, Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol 1989; 160: 439–43
   PubMed Web of Science ®Google Scholar
• Cowchock F S, Reece E A, Balaban D, Branch M D, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low‐dose heparin treatment. Am J Obst Gynecol 1992; 166: 1318–23
   PubMed Web of Science ®Google Scholar
• Silver R K, Macgregor S N, Sholl J S, Hobart J M, Neerhof M G, Ragin A. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody positive obstetric patients. Am J Obstet Gynecol 1993; 169: 1411–7
   PubMed Web of Science ®Google Scholar
• Ros J O, Tarres M U, Baucells M U, Maired J V, Solano J T. Prednisone and maternal lupus anticoagulant. Lancet 1983; 2: 576
   Google Scholar
• Branch D W. Antiphospholipid syndrome: laboratory concerns, fetal loss, and pregnancy management. Semin Perinatol 1991; 15: 230–7
   PubMedGoogle Scholar
• Chan J K H, Harris E N, Hughes G R V. Successful pregnancy following suppression of anticardiolipin antibody and anticoagulant with azathioprine in systemic lupus erythematosus. J Obstet Gynaecol 1986; 7: 16–17
   PubMedGoogle Scholar
• Price H V, Salaman J R, Laurence K M, Longmaid M. Immunosuppressive drugs and the foetus. Transplantation 1976; 21: 294–8
   PubMed Web of Science ®Google Scholar
• Frampton G, Cameron J S, Thorn M, Jones S, Raftery M. Successful removal of antiphospholipid antibody during pregnancy using plasma exchange and low‐dose prednisolone. Lancet 1987; ii: 1023–4
   Google Scholar
• Fulcher D, Stewart G, Exner T, Trudinger B, Jeremy R. Plasma exchange and the anticardiolipin syndrome in pregnancy. Lancet 1989; 2: 171
   PubMedGoogle Scholar
• Balasch J, Carmona F, Lopezsoto A, Font J, Creus M, Fabregues F, Lngelmo M, Vanrell J A. Low‐dose aspirin for prevention of pregnancy losses in women with primary antiphospholipid syndrome. Hum Reprod 1993; 8: 2234–9
   PubMed Web of Science ®Google Scholar
• Rosove M H, Tabsh K, Wasserstrum N, Howard P, Hahn B, Kalunian K C. Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies. Obstet Gynecol 1990; 75: 630–4
   PubMed Web of Science ®Google Scholar
• de Swiet M, Ward P D, Fidler J, Horsman A, Katz D, Letsky G, Peacock M, Wise P H. Prolonged heparin therapy in pregnancy causes bone demineralisation. Br J Obstet Gynecol 1983; 90: 1129–34
   PubMedGoogle Scholar
• Joffe A M, Hoskins C F, Ghitter‐Mannes S C, Mant M J. Anticoagulant therapy for prevention of spontaneous abortion in a patient with lupus anticoagulant. Am J Hematol 1988; 29: 56–7
   PubMedGoogle Scholar
• Campbell M, Tate G, Scott J S. The use of warfarin in pregnancy complicated by circulating lupus anticoagulant: a technique for monitoring. Eur J Obstet Gynecol Reprod Biol 1988; 29: 27–32
   PubMedGoogle Scholar
• Carreras L O, Perez G N, Vega H R, Casavilla F. Lupus anticoagulant and recurrent fetal loss: successful treatment with gamma‐globulin. Lancet 1988; ii: 393–4
   Google Scholar
• Wapner R J, Cowchock F S, Shapiro S S. Successful treatment in two women with antiphospholipid antibodies and refractory pregnancy losses with intravenous gamma‐globulin infusions. Am J Obstet Gynecol 1989; 161: 1271–2
   PubMed Web of Science ®Google Scholar
• Scott J R, Branch D W, Kochenour N K, Ward K. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy loss caused by antiphospholipid antibodies and Rh immunization. Am J Obstet Gynecol 1988; 159: 1055–6
   PubMed Web of Science ®Google Scholar
• Parke A, Maier D, Wilson D, Andreoli J, Ballow M. Intravenous gamma‐globulin, antiphospholipid antibodies, and pregnancy. Ann Intern Med 1989; 110: 495–6
   PubMed Web of Science ®Google Scholar
• Kaaja R, Julkunen H, Ammala P, Palosuo T, Kurki P. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies. Acta Obstet Gynecol Scand 1993; 72: 63–6
   PubMed Web of Science ®Google Scholar
• Arnout J, Spitz B, Wittevrongel C, Vanrusselt M, Van Assche A, Vermylen J. High‐dose intravenous immunoglobulin treatment of a pregnant patient with an antiphospholipid syndrome: immunological changes associated with a successful outcome. Thromb Haemostas 1994; 71: 741–7
   PubMed Web of Science ®Google Scholar
• Reece E A, Romero R, Clyne L P, Kriz N S, Hobbins J C. Lupus‐like anticoagulant in pregnancy. Lancet 1984; i: 344–5
   Google Scholar
• Petri M, Golbus M, Anderson R, Whiting‐O'Keefe Q, Corash L, Hellmann D. Antinuclear antibody, lupus anticoagulant and anticardiolipin antibody in women with idiopathic habitual abortion. A controlled, prospective study of forty‐four women. Arthritis Rheum 1987; 30: 601–6
   PubMedGoogle Scholar
• Stafford‐Brady F J, Gladman D D, Urowitz M B. Successful pregnancy in systemic lupus erythematosus with an untreated lupus anticoagulant. Arch Intern Med 1988; 148: 1647–8
   PubMedGoogle Scholar